Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article highlights that rivaroxaban, commonly associated with bleeding risks, may also cause rare non-bleeding adverse effects like liver injury and hypersensitivity.

This case report suggests that hair loss may be a potential adverse effect of rivaroxaban, though it is not listed in the product characteristics.

In this study, researchers found that niosomes, bilosomes, and spanlastic formulations can enhance the oral anticoagulation efficiency of rivaroxaban in rats, with spanlastic ranked as the most effective in prolonging clotting, prothrombin, and tail bleeding times compared to unprocessed rivaroxaban.

This review discusses the potential link between direct oral anticoagulants and hair loss, suggesting DOACs may not be a suitable alternative for patients with alopecia from traditional anticoagulants; however, no clinical results are reported.

This study observed that the incidence of hair loss as a spontaneously reported side effect of novel oral anticoagulant therapy is approximately 4.4 per 100 patient years.